An analysis from the American Cancer Society, appearing in JAMA Oncology, quantified the progress made against cancer since the passage of the National Cancer Act fifty years ago.
Combination treatment with immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated overall survival benefit for patients with melanoma that has spread to the brain, according to phase II study results published in The Lancet Oncology by researchers at MD Anderson Cancer Center.
The neoadjuvant Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone in patients with with resectable stage IB to IIIA non-small cell lung cancer, according to a prespecified interim analysis of the phase III CheckMate -816 trial.
A clinical trial conducted by the Children’s Oncology Group and funded by NCI found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia.
Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy found that combining Medimmune/AstraZeneca’s immunotherapy agent Imfinzi (durvalumab) with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma.
A team of scientists led by Rong Lu from USC and Akil A. Merchant from Cedars-Sinai introduced a genetic technology correlating gene expression signatures with cancer progression and chemotherapy resistance in leukemia.
A team from Roswell Park Comprehensive Cancer Center has identified the beta-adrenergic receptor (β-AR) as a driver of immune suppression and cancer growth in response to chronic stress, opening the possibility of targeting this receptor in cancer therapy and prevention.
University of Utah study finds risk of age-related diseases may be higher in younger B-NHL survivors
University of Utah researchers found that younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis.
The American Lung Association’s LUNG FORCE initiative released the 2021 Lung Health Barometer, a national survey that examines awareness, attitudes, and beliefs about lung health and lung cancer. This is the sixth year the survey has been conducted.
Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have shown that copper ions combined with disulfiram (DSF), a drug used for nearly 70 years as a treatment for alcoholism, may help kill and prevent the growth of medulloblastoma cancer cells in children.
